tbuckley/cabot-search huggingface dataset:
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
Authors: Daisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, Caroline Porter, Mae Woods, Spyridoula Vasileiou, Bora Lim, Masataka Suzuki
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested “Armed” OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd). We recently demonstrated that a single low-dose CAdVEC expressing interleukin-12, programmed death-ligand 1 blocker, and HSV thymidine kinase safety switch (CAdTrio) induces significant antitumor effects in patients, including complete response. Similar to previous OAd studies, all patients primarily amplified Ad-specific T cells after treatment however, CAdVEC was still able to induce clinical responses even given at a 100-fold lower dose. Methods To address the mechanisms of CAdTrio-mediated antitumor effect in patients, we analyzed patients’ samples using Enzyme-linked immunosorbent spot (ELISpot) to measure T-cell specificity and quantitative polymerase chain reaction (qPCR) to measure CAdVEC viral genome copies at tumor sites. We then evaluated potential mechanisms of CAdVEC efficacy in vitro using live-cell imaging. Based on those results, we developed a new CAdVEC additionally expressing a T-cell engager molecule targeting CD44v6 to redirect tumor-infiltrating irrelevant T cells against cancer stem cell populations (CAdTetra) for further improvement of local CAdVEC treatment. We tested its efficacy against different cancer types both in vitro and in vivo including Ad pre-immunized humanized mice. Results We found that HDAd-infected cells escape Ad-specific T-cell recognition with enhanced tumor-specific T-cell activity through immunomodulatory transgenes. Since CAdVEC treatment initially amplified Ad-specific T cells in patients, we re-direct these virus-specific T cells to target tumor cells by additionally expressing CD44v6.BiTE from CAdTetra. CAdTetra significantly controlled tumor growth, repolarizing local and systemic responses against cancer cells in both immunologically “hot” and “cold” tumor models and also induced immunologic memory against rechallenged tumors. Conclusions Our results indicate that CAdTetra effectively induces adaptive T-cell responses against cancer cells by using tumor-infiltrating irrelevant T cells.
Cost-related non-adherence to medications among adults with asthma in the USA, 2011–2022
Authors: Chun-Tse Hung, Steven R Erickson, Chung-Hsuen Wu
Journal: Thorax (2024)

Uncontrolled asthma is possibly caused by medication non-adherence, and financial hardship can be a major contributor to non-adherence. Since economic conditions and asthma management have changed over time, a comprehensive investigation of cost-related medication non-adherence (CRN) among adults with asthma is crucial.
METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer
Authors: Ling Wu, Rui Bai, Yujie Zhang, Hao Chen, Jianghua Wu, Zetao Chen, Hui Wang, Liang Zhao
Journal: Journal for ImmunoTherapy of Cancer (2024)

Objective Although immune checkpoint blockade (ICB) therapy represents a bright spot in antitumor immunotherapy, its clinical benefits in colorectal cancer (CRC) are limited. Therefore, a new target for mediating CRC immunosuppression is urgently needed. Adenomatous polyposis coli (APC) mutations have been reported as early-stage characteristic events in CRC, but the role of truncated APC in the CRC immune microenvironment remains unclear and its clinical significance has yet to be explored. Design Adenocarcinoma formation in the colon of the APC Min/+ mouse model, which displays features associated with the translation of truncated APC proteins, was induced by azoxymethane/dextran sodium sulfate. Multiplexed immunohistochemical consecutive staining on single slides and flow cytometry were used to explore the activation of immune cells and the expression of the immune checkpoint V-domain immunoglobulin suppressor of T-cell activation (VISTA) in the CRC tissues of APC WT and APC Min/+ mice. The construction of truncated APC vectors and an initial subserosal graft tumor mouse model was employed to mimic the tumor microenvironment (TME) during APC mutation. Methylated RNA immunoprecipitation-quantitative PCR assays were performed to investigate the N6-methyladenosine (m6A)-dependent transcriptional regulation of hypoxia-inducible factor-1 alpha (HIF1α) by methyltransferase-like protein 3 (METTL3). Mettl3 fl/fl vil1-cre +/− mice were used to demonstrate that targeting METTL3 is a mediator that mitigates the deleterious effects of the APC978∆-HIF1α axis on antitumor immunity. A chimeric VISTA humanized mouse model was used to evaluate the drug efficacy of the VISTA-targeted compound onvatilimab. Results We showed that APC978∆, a truncated APC protein, mediated overexpression of METTL3, resulting in m6A methylation of HIF1α messenger RNA and high expression of HIF1α. Furthermore, HIF1α promotes the migration of myeloid-derived suppressor cells to the TME by binding to the promoters of MCP-1 and MIF. In addition, HIF1α enhances the expression of the immune checkpoint VISTA on CRC cells, weakening tumor immune monitoring. Conclusions We elucidate that an underappreciated function of truncated APC in CRC is its ability to drive an immunosuppressive program that boosts tumor progression. Our work could provide a new perspective for the clinical application of immunotherapy in patients with CRC resistant to ICB therapy.
DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation
Authors: Kyra J Fuchs, Marcus Göransson, Michel G D Kester, Natasja W Ettienne, Marian van de Meent, Rob C M de Jong, Eva A S Koster, Constantijn J M Halkes, Ferenc Scheeren, Mirjam H M Heemskerk, Peter van Balen, J H Frederik Falkenburg, Sine R Hadrup, Marieke Griffioen
Journal: Journal for ImmunoTherapy of Cancer (2024)

Allogeneic stem cell transplantation (alloSCT) provides a curative treatment option for hematological malignancies. After HLA-matched alloSCT, donor-derived T cells recognize minor histocompatibility antigens (MiHAs), which are polymorphic peptides presented by HLA on patient cells. MiHAs are absent on donor cells due to genetic differences between patient and donor. T cells targeting broadly expressed MiHAs induce graft-versus-leukemia (GvL) reactivity as well as graft-versus-host disease (GvHD), while T cells for MiHAs with restricted or preferential expression on hematopoietic or non-hematopoietic cells may skew responses toward GvL or GvHD, respectively. Besides tissue expression, overall strength of GvL and GvHD is also determined by T-cell frequencies against MiHAs. Here, we explored the use of DNA barcode-labeled peptide-MHC multimers to detect and monitor antigen-specific T cells for the recently expanded repertoire of HLA-I-restricted MiHAs. In 16 patients who experienced an immune response after donor lymphocyte infusion, variable T-cell frequencies up to 30.5% of CD8 + T cells were measured for 49 MiHAs. High T-cell frequencies above 1% were measured in 12 patients for 19 MiHAs, with the majority directed against mismatched MiHAs, typically 6–8 weeks after donor lymphocyte infusion and at the onset of GvHD. The 12 patients included 9 of 10 patients with severe GvHD, 2 of 3 patients with limited GvHD and 1 of 3 patients without GvHD. In conclusion, we demonstrated that barcoded peptide-MHC multimers reliably detect and allow monitoring for MiHA-specific T cells during treatment to investigate the kinetics of immune responses and their impact on development of GvL and GvHD after HLA-matched alloSCT.
CAR T cells secreting NGF-neutralizing scFv enhance efficacy in clear cell renal cell carcinoma by relieving immunosuppression through immunosympathectomy
Authors: Peiwei Yang, Xi Chen, Fan Yu, Lan Wang, Meng Li, Zongke Bai, Hanmei Xu
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Chimeric antigen receptor (CAR) T cells have demonstrated remarkable breakthroughs in treating hematologic malignancies, yet their efficacy in solid tumors is limited by the immunosuppressive microenvironment. Sympathetic nerves significantly contribute to this immunosuppressive milieu in solid tumors. However, the impact of tumor sympathetic denervation on enhancing CAR T-cell antitumor efficacy remains unclear. Methods We screened for sympathetic gene sets in various types of cancers and investigated the association of sympathetic nerves with immunosuppression in renal clear cell carcinoma. Using antibodies to block the nerve growth factor (NGF) pathway, we explored sympathetic nerve distribution in tumor tissues and tumor progression. Additionally, we engineered CAR T cells to secrete NGF single chain fragment variable (scFv) to achieve tumor immunosympathectomy and assessed their antitumor efficacy. Bulk RNA sequencing and single-cell RNA sequencing analyses were conducted to evaluate changes in immune cell phenotypes within the tumor microenvironment. Results Blocking the NGF pathway with antibodies effectively reduced sympathetic nerve distribution in tumor tissues and delayed tumor progression. CAR T cells engineered to secrete NGF scFv achieved a similar tumor immunosympathectomy and exhibited enhanced tumor suppression. RNA sequencing analyses revealed that this augmented effect was primarily due to the inhibition of the terminal exhaustion phenotype in tumor-infiltrating CD8 T cells and the prevention of macrophage polarization from M1 to M2. This approach maintained a stronger antitumor immune state at the tumor site. Additionally, splenic T cells also exhibited a more potent immune effector phenotype following the infusion of NGF scFv-secreting CAR T cells. Conclusions Our results suggest that immunosympathectomy is a novel approach to weaken tumor microenvironment immunosuppression and synergistically enhance CAR T-cell efficacy against solid tumors.
One Year of Gluten Free Diet Impacts Gut Function and Microbiome in Celiac Disease
Authors: Carolyn M Costigan, Frederick J Warren, Anthony P Duncan, Caroline L Hoad, Nina Lewis, Trevor Hill, Colin J Crooks, Paul S Morgan, Carolina Ciacci, Paola Iovino, David S Sanders, Falk Hildebrand, Penny A Gowland, Robin C Spiller, Luca Marciani
Journal: Clinical Gastroenterology and Hepatology (2024)
Could Lentivirus Overcome the AAV Gene-Therapy Challenges in Hemophilia A?
Authors: Johnny Mahlangu
Journal: New England Journal of Medicine (2024)

Despite the unprecedented evolution of new replacement and nonreplacement therapies, many unmet needs remain with respect to the treatment of severe hemophilia A.1 These unmet needs include preventing factor VIII–induced immunogenicity, providing consistent hemostatic protection during administration of replacement therapies, ensuring lifelong administration, and preventing musculoskeletal deterioration that occurs despite replacement and nonreplacement therapies.2 Gene transfer with the use of adeno-associated virus (AAV) has evolved to address these unmet needs. To date, valoctocogene roxaparvovec, which delivers a functional B-domain–deleted F8 transgene, remains the only gene therapy licensed for the treatment of severe hemophilia A.3-5 Challenges of AAV-mediated gene therapy include . . .
Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access
Authors: Winnie Byanyima, Linda-Gail Bekker, Matthew M Kavanagh
Journal: New England Journal of Medicine (2024)

A new era of long-acting antiretrovirals for HIV treatment and prevention demands a nonlinear approach to global access with faster sharing of technology, decentralized production, and products that meet needs in the Global South.
Face Masking and Risk of Post-Intravitreal Injection Endophthalmitis: A Network Meta-Analysis of 2.6 Million Injections
Authors: Brendan K Tao, Xiaole Li, Natalie Chen, Ryan Huang, Andrew Mihalache, David Gou, Dena Zeraatkar, Jim S Xie, Marko M Popovic, Kirill Zaslavsky, Eduardo Navajas, Peter J Kertes, David T Wong, Radha P Kohly, Rajeev H Muni
Journal: Ophthalmology (2024)
Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study
Authors: So Yeon Kim, Gerard A Silvestri, Yeon Wook Kim, Roger Y Kim, Sang-Won Um, Yunjoo Im, Jung Hye Hwang, Seung Ho Choi, Jung Seop Eom, Kang Mo Gu, Yong-Soo Kwon, Shin Yup Lee, Hyun Woo Lee, Dong Won Park, Yeonjeong Heo, Seung Hun Jang, Kwang Yong Choi, Yeol Kim, Young Sik Park
Journal: Journal of Thoracic Oncology (2024)
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
Authors: L Zhou, K W Yang, S Zhang, X Q Yan, S M Li, H Y Xu, J Li, Y Q Liu, B X Tang, Z H Chi, L Si, C L Cui, H Q Guo, Z S He, J Guo, X N Sheng
Journal: Annals of Oncology (2024)
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
Authors: Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Sigal Grisariu, Batia Avni, Shlomo Elias, Miri Assayag, Tali Dubnikov-Sharon, Marjorie Pick, Rivka Alexander-Shani, Nomi Bessig, Shlomit Herr, Alaa Shehadeh, Aseel Ishtay, Shelly Pimienta, Vladimir Vainstein, Eran Zimran, Yael Cohen, Irit Avivi, Cyrille Cohen, Polina Stepensky, Moshe E. Gatt
Journal: Journal of Clinical Oncology (2024)

PURPOSE The use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This report addresses the AL patient cohort treated to date within the phase Ia/Ib clinical trial (ClinicalTrials.gov identifier: NCT04720313 ). METHODS After lymphodepletion, most AL patients were infused with 800 × 10 6 CARTs. RESULTS Sixteen patients were treated, with a median of four previous lines of therapy (range, 3-10), 14/16 were triple class refractory, and 6/16 were refractory to belantamab. Most patients (13/16) had cardiac involvement, including five with MAYO stage IIIa/IIIb at study entry. Cytokine release syndrome was frequent (14/16) but mostly low grade (grade 3: 3/16, no grade 4/5). No neurologic toxicity or treatment-related deaths were observed. There were five grade 3 AL-related organ deteriorations resolved quickly with supportive care. The overall hematologic response rate was 15/16 (94%) and complete response (CR) was 12/16 (75%). Minimal residual disease negativity was achieved in 9/14 evaluable patients. Most patients (8/13 evaluable) achieved an objective organ response. Seven patients died during long-term follow-up, three while in CR/very good partial response, and the median overall survival was 10.1 months (95% CI, 5.8 to not reached). CONCLUSION This largest clinical trial of AL patients treated with anti-BCMA CART demonstrates acceptable and manageable toxicity in a highly frail and resistant population with remarkable efficacy, leading to fast organ responses. Among patients with baseline advanced cardiac disease, deaths in the first year were frequent, suggesting that this effective therapy should be considered earlier in the course of therapy. Anti-BCMA CART may become a powerful tool for improving organ function and survival in patients with AL.
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Authors: Alok Srivastava, Aby Abraham, Fouzia Aboobacker, Gurbind Singh, Tulasi Geevar, Uday Kulkarni, Sushil Selvarajan, Anu Korula, Rutvi Gautam Dave, Mohana Shankar, Abraham S. Singh, Anbu Jeba, Navien Kumaar, Christopher Benjamin, Kavitha M. Lakshmi, Vivi Miriam Srivastava, Ramachandran V. Shaji, Sukesh C. Nair, Harrison C. Brown, Gabriela Denning, Pete Lollar, Christopher B. Doering, Trent Spencer
Journal: New England Journal of Medicine (2024)

Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)-based expression of factor VIII for the treatment of severe hemophilia A are lacking.
Omega-3 Fatty Acids as Protective Factors for Age-related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses
Authors: Can Can Xue, Hengtong Li, Marco Yu, Crystal Chun Yuen Chong, Qiao Fan, Yih-Chung Tham, Chui Ming Gemmy Cheung, Tien Yin Wong, Emily Y Chew, Ching-Yu Cheng
Journal: Ophthalmology (2024)
Optical assessment of scars after endoscopic mucosal resection of large colorectal polyps in a multicenter, community hospital setting: is routine biopsy still necessary?
Authors: Lonne W.T. Meulen, Roel M.M. Bogie, Peter D. Siersema, Bjorn Winkens, Marije S. Vlug, Frank H.J. Wolfhagen, Martine A.M.C. Baven-Pronk, Michael P.J.A. van der Voorn, M. P. Schwartz, Lauran Vogelaar, Tom C.J. Seerden, W.L. Hazen, R W.M. Schrauwen, Lorenza Alvarez Herrero, Ramon Michel Schreuder, Annick B van Nunen, Gijs J de Bruin, Willem A. Marsman, Marc de Bièvre, Robert Roomer, Rogier de Ridder, Maria Pellisé, Michael J. Bourke, Ad Masclee, Leon MG Moons
Journal: Endoscopy (2024)

Background and study aims: Piecemeal EMR of large (≥20mm) non-pedunculated colorectal polyps (LNPCPs) is succeeded by a 6-month surveillance endoscopy to evaluate the post-EMR scar for recurrence. Data from expert centers suggest that routine tattoo placement and scar biopsies can be omitted, but data from community hospitals are lacking. Patients and methods: In a post-hoc analysis of the STAR-LNPCP study (NTR7477), containing prospective data on 6-month post-pEMR scar assessments in 30 Dutch community hospitals (October 2019 to May 2022), the agreement between optical assessment and histological confirmation by routine biopsies was evaluated. Documentation of optical characteristics, imaging, and biopsies of the post-EMR scar were performed according to a standardized protocol. Results: In 1277 post-EMR scar assessments, identification of the scar was achieved in 1215/1277 (95%). Tattoo placement did not influence scar identification. Scar biopsy was performed in 1050/1215 cases (86%). Recurrences were seen in 200/1050 cases (19%). There was a good agreement between optical assessment of recurrence and histological confirmation (Cohen’s kappa 0.78 [0.73-0.83]). The NPV was 98% [97-99%] and the PPV was 74% [68-80%]. Higher false positive rate was seen after prior use of clips (11% vs. 5%, p=0.017). Dedicated endoscopists identified the scar more often (96% vs. 88%, p&lt;0.001), and showed a lower optical recurrence miss rate (1%vs. 3%, p=0.111) compared to non-dedicated endoscopists. Conclusion: Based on this multicenter community hospital study, routine tattoo placement and scar biopsies of the post-EMR scar can be omitted. Assessment of post-EMR scars by dedicated endoscopists is advised.
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
Authors: Carolina Seybert, Nina Schimmers, Lucio Silva, Joost J Breeksema, Jolien Veraart, Bárbara S Bessa, Dora d'Orsi, Robert A Schoevers, Albino J Oliveira-Maia
Journal: The Lancet Psychiatry (2024)
The 2024 small island developing states report of the Lancet Countdown on health and climate change
Authors: Georgiana M Gordon-Strachan, Stephanie Y Parker, Heather C Harewood, Pablo A Méndez-Lázaro, Salanieta T Saketa, Kimalie F Parchment, Maria Walawender, Abdullahi O Abdulkadri, Paul J Beggs, Daniel F Buss, Riley J Chodak, Shouro Dasgupta, Olga De Santis, Natalie G Guthrie-Dixon, Saria Hassan, Harry Kennard, Sandeep B Maharaj, Kwesi G Marshall, Shelly R McFarlane, Kimberley S McKenzie, Maziar Moradi-Lakeh, Madhuvanti Murphy, Michelle A Mycoo, Roannie Ng Shiu, Megan B O'Hare, Christopher A L Oura, Fereidoon Owfi, Ali Owfi, Karen A Polson, Mahnaz Rabbaniha, Elizabeth J Z Robinson, David C Smith, Meisam Tabatabaei, Lanea L Tuiasosopo, Marina Romanello
Journal: The Lancet Global Health (2024)
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial
Authors: Guillaume Martel, François Martin Carrier, Christopher Wherrett, Tori Lenet, Katlin Mallette, Karine Brousseau, Leah Monette, Aklile Workneh, Monique Ruel, Elham Sabri, Heather Maddison, Melanie Tokessy, Patrick B Y Wong, Franck Vandenbroucke-Menu, Luc Massicotte, Michaël Chassé, Yves Collin, Michel-Antoine Perrault, Élodie Hamel-Perreault, Jeieung Park, Shirley Lim, Véronique Maltais, Philemon Leung, Richard W D Gilbert, Maja Segedi, Jad Abou Khalil, Kimberly A Bertens, Fady K Balaa, Timothy Ramsay, Alan Tinmouth, Dean A Fergusson
Journal: The Lancet. Gastroenterology & hepatology (2024)
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS
Authors: Carl Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M Voorhees, Irwindeep Sandhu, Matthew W Jenner, Dean Smith, Michele Cavo, Niels W.C.J. van de Donk, Meral Beksac, Phillippe Moreau, Hartmut Goldschmidt, Diego Vieyra, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, Craig C. Hofmeister
Journal: Blood (2024)

Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were randomized to intravenous daratumumab 16 mg/kg following a Long intense (n = 41), Intermediate (n = 41), or Short intense (n = 41) dosing schedule. At a combined median follow-up of 85.2 months, in the Long intense, Intermediate, and Short intense arms complete response or better rates were 4.9%, 9.8%, and 0%; overall response rates were 58.5%, 53.7%, and 37.5%; progressive disease/death rates were 0.096, 0.102, and 0.109 (P &amp;lt;0.0001 for all arms); and median progression-free survival was not reached, 84.4, and 74.1 months, respectively. Median overall survival was not reached in any arm. Thirty-six patients in the Long intense or Intermediate arms continued daratumumab in an optional extension phase after completing 20 cycles of per protocol treatment. Median (range) duration of study treatment was 44.0 (1.0-91.6), 35.2 (1.9-90.6), and 1.6 (0.1-1.9) months in the Long intense, Intermediate, and Short intense arms, respectively. No new safety signals were observed. With extended follow-up (median, ~7 years), these data highlight the tolerability of daratumumab and support ongoing trials investigating daratumumab as an early intervention for SMM. ClinicalTrials.gov Identifier: NCT02316106.
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes
Authors: Ciara L Freeman, Jerald Noble, Meghan Menges, Ricardo Villanueva, Justyn Y Nakashima, Nicholas B Figura, R. Petter Tonseth, Dietrich Werner Idiaquez, Lawrence Skelson, Eric C Smith, Julieta Abraham-Miranda, Salvatore Corallo, Gabriel De Avila, Omar Castaneda Puglianini, Hien D Liu, Melissa Alsina, Taiga Nishihori, Kenneth H Shain, Rachid C Baz, Brandon J Blue, Ariel Grajales-Cruz, John M. Koomen, Reginald M Atkins, Doris K Hansen, Ariosto Siqueira Silva, Jongphil Kim, Yoganand Balagurunathan, Frederick L Locke
Journal: Blood (2024)
The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas
Authors: Nermin Kady, Suhaib Abdelrahman, Ahmar Rauf, Alyssa Burgess, Jonathan Weiss, Hirushi Gunasekara, Neal Thomas Ramseier, Ira P Maine, Alejandro Zevallos-Morales, Vanessa Perez-Silos, Ashley Wolfe, Alexandra Hristov, Noah A Brown, Kedar V Inamdar, Maria Sverdlov, Ying Samuel Hu, Carlos Murga-Zamalloa, Chenguang Wang, Ryan A Wilcox
Journal: Blood (2024)